Verovaccines has developed the first recombinant subunit vaccine against bluetongue virus-3 (BTV-3), which is currently affecting sheep and cattle in Europe, in just a few months. Thanks to an innovative vaccine platform, the first vaccine products were generated in just a few weeks.

The approval dossier is already 90% complete and the company expects to receive emergency authorisation this year. The new virus-free vaccine is characterised by its DIVA capability, which supports effective outbreak control.

Verovaccines also plans to use its platform for the development of further vaccines and sees great potential for rapid response to new emerging diseases. The collaboration with the Friedrich-Loeffler-Institut and the commitment of the 12-member team have contributed significantly to the success. CEO Dr Hanjo Hennemann emphasises that the company's technology platform is used both for rapid emergency responses and for the cost-effective full registration of vaccines.

The spin-off of Verovaccines GmbH from Martin Luther University Halle-Wittenberg was funded by the "Gründungsoffensive Biotechnologie" (GO-Bio) of the Federal Ministry of Education and Research (BMBF).